Abstract:Fetal development in an adverse in utero environment significantly increases the risk of developing metabolic diseases in later life, including dyslipidemia, non-alcoholic fatty liver diseases and diabetes. The aim of this study was to determine whether improving the in utero fetal growth environment with a placental nanoparticle gene therapy would ameliorate fetal growth restriction (FGR)-associated dysregulation of fetal hepatic lipid and glucose metabolism-related signaling pathways. Using the guinea pig maternal nutrient restriction (MNR) model of placental insufficiency and FGR, placenta efficiency was significantly improved following three administrations of a non-viral polymer-based nanoparticle gene therapy to the placenta from mid-pregnancy (gestational day 35) until gestational day 52. The nanoparticle gene therapy transiently increased expression of human insulin-like growth factor 1 (hIGF1) in placenta trophoblast. Fetal liver tissue was collected near-term at gestational day 60. Fetal sex specific differences in liver gene and protein expression of pro-fibrosis and glucose metabolism-related factors were demonstrated in sham-treated FGR fetuses but not observed in FGR fetuses who received placental hIGF1 nanoparticle treatment. Increased plasma bilirubin, and indirect measure of hepatic activity, was also increased with placental hIGF1 nanoparticle treatment. We speculate that the changes in liver gene and protein expression and increased liver activity that result in similar expression profiles to appropriately growing Control fetuses might confer protection against increased susceptibility to aberrant liver physiology in later-life. Overall, this work opens avenues for future research assessing the translational prospect of mitigating FGR-induced metabolic derangements.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the abnormal changes in liver lipid and glucose - metabolism - related signaling pathways caused by fetal growth restriction (FGR). Specifically, the study aims to improve the intra - uterine fetal growth environment through nanoparticle - based gene therapy to alleviate FGR - related fetal liver metabolic disorders. The study used a guinea pig maternal nutrient restriction (MNR) model to simulate placental insufficiency and FGR, and observed the effect on fetal liver metabolism by injecting non - viral polymeric nanoparticles containing the human insulin - like growth factor 1 (hIGF1) gene into the placenta. ### Research Background - **Fetal Growth Restriction (FGR)**: It refers to the failure of the fetus to reach its genetic growth potential during pregnancy, usually caused by placental insufficiency or maternal factors. - **Risk of Metabolic Diseases**: FGR not only affects the immediate health of the fetus but also increases the risk of metabolic diseases (such as dyslipidemia, non - alcoholic fatty liver disease, and diabetes) in adulthood. - **Role of the Liver in Metabolism**: The liver is a key organ in regulating lipid and glucose metabolism, and changes in its early development and function are closely related to FGR. ### Research Objectives - **Improve Placental Function**: By injecting nanoparticles containing the hIGF1 gene into the placenta, improve placental efficiency, increase the glucose level in fetal blood, reduce the cortisol level in fetal blood, and thus improve fetal weight. - **Evaluate Liver Metabolic Changes**: Study the changes in gene and protein expression related to lipid and glucose metabolism in the liver of FGR fetuses after receiving placental hIGF1 nanoparticle treatment, and whether these changes can alleviate the metabolic disorders caused by FGR. ### Main Findings - **Effects of Placental hIGF1 Nanoparticle Treatment**: - Improved placental function and increased fetal weight. - Increased the glucose level in fetal blood and reduced the cortisol level. - Alleviated FGR - related fetal liver metabolic disorders, especially the abnormalities in lipid and glucose - metabolism - related signaling pathways. - **Sex - Specific Differences**: - In untreated FGR fetuses, sex - specific differences in liver gene and protein expression were observed. - In FGR fetuses receiving placental hIGF1 nanoparticle treatment, these sex - specific differences were not obvious. ### Conclusions - **Potential Clinical Significance**: This study shows that by improving placental function, FGR - caused fetal liver metabolic disorders can be alleviated, which may help reduce the risk of metabolic diseases in adulthood. - **Future Research Directions**: Further study the long - term effects of this treatment method and its application prospects in humans. ### Keywords - Fetal liver - Placenta - Nanoparticle - Fetal growth restriction - Glucose - Lipid - Metabolism Through these research results, the authors hope to provide new directions for future research on how to prevent metabolic diseases caused by FGR by improving placental function.

Placental hIGF1 nanoparticle gene therapy in guinea pigs ameliorates fetal growth restriction-associated changes in hepatic lipid and glucose metabolism-related signaling pathways in a fetal sex-specific manner

Placental Nanoparticle-mediated IGF1 Gene Therapy Corrects Fetal Growth Restriction in a Guinea Pig Model

Maternal-fetal interfaces transcriptome changes associated with placental insufficiency and a novel gene therapy intervention

Placental treatment with insulin-like growth factor 1 via nanoparticle differentially impacts vascular remodeling factors in guinea pig sub-placenta/decidua

Mid-pregnancy placental transcriptome in a model of placental insufficiency with and without novel intervention

Anti-placental Growth Factor Antibody Ameliorates Hyperoxia-Mediated Impairment of Lung Development in Neonatal Rats

Size-dependent Placental Retention Effect of Liposomes in ICR Pregnant Mice: Potential Superiority in Placenta-Derived Disease Therapy

Insulin-like growth factor 1 signaling in the placenta requires endothelial nitric oxide synthase to support trophoblast function and normal fetal growth

Maternal Uterine Artery Adenoviral Vascular Endothelial Growth Factor (Ad.VEGF-A165) Gene Therapy Normalises Fetal Brain Growth and Microglial Activation in Nutrient Restricted Pregnant Guinea Pigs

Integrated Placental Modelling of Histology with Gene Expression to Identify Functional Impact on Fetal Growth

PSII-34 Placental GLUT3 (SLC2A3) RNA interference: Impact on fetal growth at mid-gestation

Maternal pyrimidine nucleoside supplementation regulates fatty acid, amino acid and glucose metabolism of neonatal piglets

Nanoparticle-mediated delivery of placental gene therapy via uterine artery catheterization in a pregnant rhesus macaque

FGR-associated Placental Insufficiency and Capillary Angiogenesis Involves Disruptions in Human Placental Mirnas and Mrnas

Liposome-Encapsulated Anti-inflammatory Proteins for Targeted Delivery to the Placenta to Treat Fetal Growth Restriction

Effects of excess thromboxane A2 on placental development and nutrient transporters in a Mus musculus model of fetal growth restriction†

Targeted Delivery of Epidermal Growth Factor to the Human Placenta to Treat Fetal Growth Restriction

Human sFLT1 Leads to Severe Changes in Placental Differentiation and Vascularization in a Transgenic hsFLT1/rtTA FGR Mouse Model

A genetically small fetus impairs placental adaptations near term

Placenta-tropic VEGF mRNA lipid nanoparticles ameliorate murine pre-eclampsia